Pharmaceutical Care Services and Results in Project ImPACT: HyperlipidemiaBenjamin M. Bluml, James M. McKenney(Virginia Commonwealth University), Mark J. CzirakyJournal of the American Pharmaceutical Association (1996)March 1, 200010.1016/s1086-5802(16)31059-2Cited by 259SaveCiteExport RISWatch citationsAbstractRelated PapersSummary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)Scott M. Grundy|JAMA|1993|27.9kRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Anders Olsson, John J.V. McMurray, G Thorgeirsson et al.|The Lancet|1994|8.5kThe Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsFrank M. Sacks, Marc A. Pfeffer, Lemuel A. Moyé et al.|New England Journal of Medicine|1996|7.5kPrevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaJames Shepherd, Stuart M. Cobbe, Ian Ford et al.|New England Journal of Medicine|1995|7.5kPrimary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJohn R. Downs, Michael Clearfield, Stephen E. Weis et al.|JAMA|1998|5.3k